Get Started for FREE
Sign up with Facebook Sign up with X
I don't have a Facebook or a X account
 Your new post is loading...
Your new post is loading...
Scoop.it!
We describe the production and characterization of human monoclonal antibodies (mAb) specific for the major hepatitis B virus (HBV) S protein. Via Krishan Maggon 
Scoop.it!
The increasing incidence of acyclovir (ACV) and multidrug-resistant strains in patients with corneal HSV-1 infections leading to Herpetic Stromal Keratitis (HSK) is a major health problem in industrialized countries and often results in blindness. Via Krishan Maggon
Krishan Maggon 's curator insight,
January 15, 2015 3:09 AM
Prevention of Herpes Simplex Virus Induced Stromal Keratitis by a Glycoprotein B-Specific Monoclonal AntibodyAdalbert Krawczyk ,
* E-mail: adalbert.krawczyk@uni-due.de Affiliation: Institute of Virology, University Hospital Essen, University of Duisburg-Essen, Essen, Germany ⨯Miriam Dirks,Affiliation: Institute of Virology, University Hospital Essen, University of Duisburg-Essen, Essen, Germany ⨯Maren Kasper,Affiliation: Ophtha-Lab, Department of Ophthalmology at St. Franziskus Hospital, Muenster, Germany ⨯Anna Buch,Affiliation: Institute of Virology, Hannover Medical School, Hannover, Germany ⨯Ulf Dittmer,Affiliation: Institute of Virology, University Hospital Essen, University of Duisburg-Essen, Essen, Germany ⨯Bernd Giebel,Affiliation: Institute for Transfusion Medicine, University Hospital Essen, Essen, Germany ⨯Lena Wildschütz,Affiliation: Ophtha-Lab, Department of Ophthalmology at St. Franziskus Hospital, Muenster, Germany ⨯Martin Busch,Affiliation: Ophtha-Lab, Department of Ophthalmology at St. Franziskus Hospital, Muenster, Germany ⨯Andre Goergens,Affiliation: Institute for Transfusion Medicine, University Hospital Essen, Essen, Germany ⨯Karl E. Schneweis,Affiliation: Institute of Virology, University Medical Center Bonn, Bonn, Germany ⨯Anna M. Eis-Hübinger,Affiliation: Institute of Virology, University Medical Center Bonn, Bonn, Germany ⨯Beate Sodeik,Affiliation: Institute of Virology, Hannover Medical School, Hannover, Germany ⨯Arnd Heiligenhaus,Affiliation: Ophtha-Lab, Department of Ophthalmology at St. Franziskus Hospital, Muenster, Germany ⨯Michael Roggendorf,Affiliation: Institute of Virology, University Hospital Essen, University of Duisburg-Essen, Essen, Germany ⨯Dirk BauerAffiliation: Ophtha-Lab, Department of Ophthalmology at St. Franziskus Hospital, Muenster, Germany ⨯ Published: January 14, 2015DOI: 10.1371/journal.pone.0116800 |
Scoop.it!
Chemotherapy and/or radiation therapy are widely used as cancer treatments, but the antitumor effects they produce can be enhanced when combined with immunotherapies. Chemotherapy kills tumor cells, but it also releases tumor antigen and allows the cross-presentation of the tumor antigen to trigger antigen-specific cell-mediated immune responses. Promoting CD4+ T helper cell immune responses can be used to enhance the cross-presentation of the tumor antigen following chemotherapy. The pan HLA-DR binding epitope (PADRE peptide) is capable of generating antigen-specific CD4+ T cells that bind various MHC class II molecules with high affinity and has been widely used in conjunction with vaccines to improve their potency by enhancing CD4+ T cell responses. Here, we investigated whether intratumoral injection of PADRE and the adjuvant CpG into HPV16 E7-expressing TC-1 tumors following cisplatin chemotherapy could lead to potent antitumor effects and antigen-specific cell-mediated immune responses. We observed that treatment with all three agents produced the most potent antitumor effects compared to pairwise combinations. Moreover, treatment with cisplatin, CpG and PADRE was able to control tumors at a distant site, indicating that our approach is able to induce cross-presentation of the tumor antigen. Treatment with cisplatin, CpG and PADRE also enhanced the generation of PADRE-specific CD4+ T cells and E7-specific CD8+ T cells and decreased the number of MDSCs in tumor loci. The treatment regimen presented here represents a universal approach to cancer control. Via Krishan Maggon
Gilbert C FAURE's insight:
PADRE pan HLA-DR binding eitope
Krishan Maggon 's curator insight,
February 4, 2015 3:20 AM
Citation: Song L, Yang M-C, Knoff J, Wu T-C, Hung C-F (2014) Cancer Immunotherapy Employing an Innovative Strategy to Enhance CD4+ T Cell Help in the Tumor Microenvironment. PLoS ONE 9(12): e115711. doi:10.1371/journal.pone.0115711 |
Citation: Cerino A, Bremer CM, Glebe D, Mondelli MU (2015) A Human Monoclonal Antibody against Hepatitis B Surface Antigen with Potent Neutralizing Activity. PLoS ONE 10(4): e0125704. doi:10.1371/journal.pone.0125704